Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs

Abstract

BackgroundNeuroinflammatory adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to date have compared the real‐world risk of TNFs to other new users of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARD). The objective of this study is to describe the risk of neuroinflammatory disease after initiation b/tsDMARDs.MethodsThis new‐user comparative effectiveness cohort study utilized a large US‐based electronic health‐records database to describe the unadjusted incidence of neuroinflammatory adverse events over a 3‐year period. The cohort included patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis initiating treatment with a TNFi (n=93,661) or other b/tsDMARD (n=38,354) were included.ResultsAmong 132,015 patients included in the analysis, the most common first biologic agent was a TNF inhibitor, the unadjusted incidence of neuroinflammatory events was numerically lower among new users of TNF inhibitors (incidence 1.34 per 1,000 patient‐years) as compared to the combined non‐TNF group (1.69 per 1,000 patient‐years). There was no significant association between TNF exposure and neuroinflammatory events as compared to the combined non‐TNF b/tsDMARDs overall (hazard ratio [HR] 1.01, 95% confidence interval [CI] 0.75‐1.36) and within each disease group.ConclusionThe overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared to new users of other b/tsDMARDs. Meta‐analyses of randomized trials should be conducted to corroborate these findings, which may be affected by channeling bias.